Objective: To evaluate the impact of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa on bradykinesia, dyskinesia, and sleep quality using self-reported Hauser diaries and Parkinson’s KinetiGraph (PKG) watch scores.
Background: CSCI foslevodopa/foscarbidopa is a novel treatment for advanced Parkinson’s Disease (PD), designed to address motor fluctuations and dyskinesias. Phase 3 trials indicate that CSCI improves “on” time without troublesome dyskinesias and reduces “off” time compared to oral formulations. However, real-world data remains limited.
Method: Patients with PD transitioning from oral levodopa/carbidopa to CSCI foslevodopa/foscarbidopa were recruited. Each patient wore a PKG watch for seven days at three time points: baseline (pre-CSCI), 6 weeks post-CSCI, and 12 weeks post-CSCI. They also completed Hauser diaries at these intervals. Estimated percentages of “off” time, dyskinetic time, and “on” time without troublesome dyskinesias were calculated from the diaries. Descriptive statistics were applied, and repeated measures ANOVAs were used for comparisons.
Results: Preliminary results show that at baseline, PKG data showed an average percentage time bradykinetic at 32.4%, dyskinetic at 25.75% and with tremor 2.5%. At 6 weeks post CSCI commencement, 40% of patients showed a reduction in bradykinesia scores, 100% demonstrated reduced dyskinesia scores, and 80% reported improved sleep quality.
Conclusion: We demonstrate changes in bradykinesia, dyskinesias and sleep scores when switching from oral levodopa/carbidopa to CSCI foslevodopa/foscarbidopa.
References: 1.Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Soileau, Michael J et al. The Lancet Neurology, Volume 21, Issue 12, 1099 – 1109
To cite this abstract in AMA style:
M. Bradley, E. Donlon, A. Gallagher, C. O'Keefe, J. Inocentes, F. Ruggieri, R. Reilly, R. Walsh, T. Lynch, C. Fearon. Effect of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on motor fluctuations, dyskinesia, and sleep; subjective vs. PKG watch recordings. [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/effect-of-continuous-subcutaneous-infusion-of-foslevodopa-foscarbidopa-on-motor-fluctuations-dyskinesia-and-sleep-subjective-vs-pkg-watch-recordings/. Accessed October 5, 2025.« Back to 2025 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/effect-of-continuous-subcutaneous-infusion-of-foslevodopa-foscarbidopa-on-motor-fluctuations-dyskinesia-and-sleep-subjective-vs-pkg-watch-recordings/